deliv oper revenu growth high end guidanc
compani experienc weak medic deliveri nutrit sale op
margin expans fell modestli short expect howev post good ep
result rais ep guidanc remain track solid sale growth
despit challeng notch sale ep growth
bax revenu beat forecast share street
revenu result reflect report growth constant currenc growth
oper growth year-over-year basi given oper sale growth
land high end manag guidanc view overal sale
show favor adjust gross margin bp ahead street forecast
bp year year underli oper expans partli off-set
fx impact increment suppli chain cost adjust oper margin
bp shi consensu expect though bp year year reflect
underli oper gain bp weigh upon fx loss
transit servic agreement incom shire report adjust ep
quarter cent ahead assumpt share street
note post net incom model
ad roughli cent bottom line tax
view weak medic deliveri nutrit temporari
area merit addit explan medic deliveri nutrit medic
deliveri sale came compar consensu
estim declin last year constant currenc basi three
factor work one continu gain new custom large-
volum parenter lvp realloc volum mexico
time addit somewhat slower anticip compani
nonetheless confid abil gain new custom experienc
lower sale small-volum parenter svp lag effect hurrican
maria though product volum steadili improv svp suppli level remain
tight thu unabl restor distributor partner cardin owen
 minor medlin etc back pre-hurrican suppli level svp product
quarter howev manag optimist near-term improv
cite progress mini-bag resolut septemb mini-bag three
call lower intern sale result compani realloc solut
volum respect nutrit divis sale fell short
street forecast project sale declin overal
constant currenc basi stem weak sale fell
last year indic experienc delay custom return
pre-hurrican histor purchas level setback may take longer fix
problem spot lvp svp medic deliveri discuss six-
eight-month recoveri timelin compani priorit work hospit
custom reinforc avail product recaptur sale
pleas see page report import disclosur
compani split allow baxter better focu deliv margin expans
top bottom line growth opportun longer term new baxter
hamper low singl digit top line growth trajectori lower oper
ebitda margin profil rel peer earli go clearer path forward
abl acceler top line growth better expect margin expans
opportun could bolster long-term outlook given top-lin margin profil
new baxter believ compani deserv trade premium med tech peer
current valuat keep us market perform
focus support compani
oper cash flow track grow
new tuck-in bolt-on acquisit
expect gener top-lin
gambro margin synergi deliv
improv ahead expect
om ebitda margin expans
opportun realiz sooner
pipelin opportun acquisit
contribut next five year
gambro margin synergi fail
meet key benchmark improv
om expans come
pipelin fail deliv
 fail produc new top-lin
diversifi global healthcar compani develop medic
devic product use hospit kidney dialysi center nurs home rehabilit
center clinic medic research laboratori patient in-hom use
biopharma solut also chronic acut product offer renal
divis gener total revenu medic product sale
complet acquisit gambro ab largest acquisit histori
bolster renal busi product portfolio juli spun bioscienc
divis form baxalta acquir shire
busi unit pick slack
encourag bax product categori abl counterbal
issu experienc medic deliveri nutrit show
standout sale well ahead forecast
consensu pharmaceut sale growth report basi
constant currenc basi oper basi growth
manag indic clari contribut global also strong acut
therapi sale improv year year constant currenc basi though
larg anticip sale compar estim
street forecast sale repres anoth area out-performance
improv constant currenc basi vs thank increas demand
bax contract manufactur new custom well increment demand
exist one sale total compar expect
street consensu renal sale advanc constant currenc
basi match street forecast though modestli short
estim note solid growth pd therapi global along increas
sale intern compani hd busi lastli advanc surgeri
deliv sale oper year year
consensu line target
rais bar ep guidanc
top line full year continu target constant currenc revenu growth
approxim oper growth compani adjust
report revenu guidanc previous cite impact currenc
impli report revenu roughli compani guid earlier
year currenc benefit favor ep forecast
rang previous compar street
current assumpt importantli rel updat manag lower
full-year tax rate assumpt reduc project share count
also lower net interest expens project
increas adjust incom forecast
chang amount benefit roughli cent math
greater magnitud latest annual ep guidanc rais make us
comfort revis target achiev forecast revenu
growth approxim oper constant currenc basi
remind compani face second-toughest oper sale growth comparison
year follow easiest growth acceler need
partli reflect unassum comp bax report revenu guidanc
growth suggest total sale obvious less current
street forecast still assum currenc tailwind see currency-
driven shortfal concern final compani guid ep
incorpor consensu
sale growth benefit new product favor comp
think likelihood compani reach oper sale growth
full-year basi strong given benefit new product launch
oper sale growth comp weve highlight busi unit
expect renal organ growth unchang prior guidanc
medic deliveri growth vs previous growth
vs previous nutrit growth advanc
surgeri growth unchang acut therapi growth
previous growth bax busi vs lsd declin previous
multipl new product includ two major launch drive sale growth
balanc year advanc surgeri compani recent launch tisseel
prima europ recothrom preveleak renal
product earli launch kaguya system sharesourc japan
success thu far present nearli japan end-stag renal diseas patient
treat via in-cent hemodialysi thu kaguya share lot function
amia tailor local market face signific growth outlook
patient opt pd pd substanti under-penetrated japan repres
multi-year opportun compani also meaning launch
version nine sigma spectrum pump platform iter enhanc
respect auto-program featur two-way wireless connect addit
sever launch like new crrt machin new hemofiltr devic
along geograph expans clari acquisit still slate add
sale unchang strengthen compani presenc gener
pharmaceut space theranova compani advanc develop
product two new trial addit recent launch updat iter
oxiri membran use prismaflex system manag sepsi
product help filter remov excess level cytokin endotoxin
inflammatori mediat patient blood repres mean augment
compani presenc acut renal market
compani remain well-posit
bax outlook appear
revenu growth pois
importantli continu believ enhanc intern program high-
growth compani capac multibillion-dollar deal like
pursu smaller tuck-in acquisit like recent move product
deal carri fewer integr risk show better return metric thursday
confer call manag reiter three key metric sustain revenu
growth that accret bax growth rate strong market posit margin
accret bax current margin show clear path improv
compani identifi enough target meet criteria manag
said overal valu stall recent evalu like turn share
buyback dividend deploy capit
recent investor day may rais estim yet updat view
compris adjust oper margin vs previous non-
gaap ep rang compani offer last
juli get expect constant currenc sale growth compound-annual-growth-rate
acceler later period free cash flow project
oper cash flow compani highlight improv free
cash flow time look target
anticip adjust oper margin non-gaap ep
compani believ constant currenc sale growth compound-annual-growth-rate step
result averag full period within next
bp adjust oper margin improv forecast bp
come gross margin expans remain bp stem
oper cost reduct compani anticip free cash flow
oper cash flow plan capit expenditur note
may soon achiev rate free cash flow convers consist
doubl rate compani capit alloc strategi remain
consist reinvest busi target dividend pay-out ratio time
engag intens focu return buy back stock
believ six therapeut area oper show combin weight
averag market growth rate compani think growth
compound-annual-growth-rate area period around achiev above-market
result everywher except expect share compound-annual-growth-rate
market largest segment renal target sale compound-annual-growth-rate
interv roughli bp ahead what expect total market
medic deliveri growth peg clinic nutrit advanc
surgeri acut therapi look period
whole anticip new product sale geograph expans contribut
growth within lrp amount bp growth roughli
bp come oper growth compani expect new product revenu
contribut total renal medic
deliveri account almost total project sale contribut
respect recent comment fda warn
letter receiv concern newli acquir clari facil ahmedabad india
compani indic receipt warn letter clari doesnt caus make
chang current long-rang guidanc importantli ensur disrupt
new product intend bring market time frame say
evalu potenti manufactur locat includ contract manufactur
organ surpris issuanc post-acquisit warn letter
fda frequent dispens especi acquir entiti show lower qualiti
standard acquir compani believ bax situat clari
manag recent commentari indic
set valuat argument asid believ feasibl bax long-term project
reduc invest risk associ stock make outlook attract rel
peer struggl even full-year guidanc go forward believ stock
driven mostli quarterli result see upsid current street ep project
given compani margin initi price target share continu
deriv appli valuat multipl ep ebitda
estim respect averag result
cowen compani
chg medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recvr gain incom non-controlling inc inc oper ex-intang restructur non-recur gain share compani report cowen compani estimatest result mm reportedour estim cowen
cowen compani
chg product total ww ww deliveri ww ww ww surgeri ww therapi ww ww compani report cowen compani estim report estim cowen
cowen compani
year end decemb end decemb end decemb medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling intang amort inc inc oper ex-intang oper ep includ intang restructur non-recur gain share per exclud one-tim item cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
